Inhibikase Therapeutics Inc (IKT NASDAQ) stock market data APIs
$1.6041
0.03(1.9%)
as of November 4, 2025
Try our APIs with
free plan!
Inhibikase Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is based in Atlanta, Georgia.
Prev. Close
1.6041
Open
1.6311
High
1.713
Low
1.5489
52 wk Range
1.33-4.2
Market Cap
118 M
Shares Outstanding
74 517 K
Revenue
1
EPS
-0.11
Beta
0.89
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Inhibikase Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Inhibikase Therapeutics Inc data using free add-ons & libraries
Get Inhibikase Therapeutics Inc Fundamental Data
Inhibikase Therapeutics Inc Fundamental data includes:
- Net Revenue: 1
- EBITDA: -44 136 512
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-14
- EPS/Forecast: -0.08
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Inhibikase Therapeutics Inc News
New
These stocks are moving in today's pre-market session
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. [premarket] PRE-MARKET GAIN...
Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity
BOSTON and ATLANTA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics...
Inhibikase Therapeutics shareholders elect directors and approve equity plan changes
Inhibikase Therapeutics, Inc. (NASDAQ:IKT), a pharmaceutical company currently trading near $1.95 and showing a strong 17.47% gain over the past week, held its 2025 Annual Meeting of Stockholders on F...
Ludwig Enterprises appoints Garth Lees-Rolfe as independent director
Ludwig Enterprises, Inc. (OTC:LUDG) announced the appointment of Garth Lees-Rolfe as an independent director, effective Monday. The decision was made by the company’s board of directors and was disc...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
